SynthesisAJNR. American journal of neuroradiology2017
Discrimination between Glioma Grades II and III Using Dynamic Susceptibility Perfusion MRI: A Meta-Analysis.
Synthesis in AJNR. American journal of neuroradiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Amide proton transfer-weighted MRI in distinguishing high- and low-grade gliomas: a systematic review and meta-analysis.Neuroradiology · 2019Pooled it
- Arterial spin labeling MR imaging for differentiation between high- and low-grade glioma-a meta-analysis.Neuro-oncology · 2018Pooled it
- Discrimination between primary low-grade and high-grade glioma withThe British journal of radiology · 2018Pooled it
- Predictive efficacy and role of 2HG in MGMT promoter methylation in gliomas: a retrospective study based on MRS and mediator variable analysis.British journal of cancer · 2025Article
- Article
- Advanced MRI, Radiomics and Radiogenomics in Unravelling Incidental Glioma Grading and Genetic Status: Where Are We?Medicina (Kaunas, Lithuania) · 2025Review
- Statistical plots in oncologic imaging, a primer for neuroradiologists.The neuroradiology journal · 2024Review
- Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI.European radiology · 2024Article
- Differentiation of astrocytoma between grades II and III using a combination of methionine positron emission tomography and magnetic resonance spectroscopy.World neurosurgery: X · 2023Article
- A rare, giant, anaplastic oligodendroglioma.Radiology case reports · 2023Article
- Tumor volume and calcifications as indicators for preoperative differentiation of grade II/III diffuse gliomas.Journal of neuro-oncology · 2023Article
- Article
- The Use ofDiagnostics (Basel, Switzerland) · 2022Review
- Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Hemodynamic Imaging in Cerebral Diffuse Glioma-Part A: Concept, Differential Diagnosis and Tumor Grading.Cancers · 2022Review
- Review
- CombiningJournal of neuro-oncology · 2021Article
- MRI biomarkers in neuro-oncology.Nature reviews. Neurology · 2021Review
- Exploring diagnostic performance of T2 mapping in diffuse glioma grading.Quantitative imaging in medicine and surgery · 2021Article
- Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML).Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDSC perfusion has been evaluated in the discrimination between low-grade and high-grade glioma but the diagnostic potential to discriminate beween glioma grades II and III remains unclear. PURPOSE: Our aim was to evaluate the diagnostic accuracy of relative maximal CBV from DSC perfusion MR imaging to discriminate glioma grades II and III. DATA SOURCES: A systematic literature search was performed in PubMed/MEDLINE, Embase, Web of Science, and ClinicalTrials.gov. STUDY SELECTION: Eligible studies reported on patients evaluated with relative maximal CBV derived from DSC with a confirmed neuropathologic diagnosis of glioma World Health Organization grades II and III. Studies reporting on mean or individual patient data were considered for inclusion. DATA ANALYSIS: Data were analyzed by using inverse variance with the random-effects model and receiver operating characteristic curves describing optimal cutoffs and areas under the curve. Bivariate diagnostic random-effects meta-analysis was used to calculate diagnostic accuracy. DATA SYNTHESIS: Twenty-eight studies evaluating 727 individuals were included in the meta-analysis. Individual data were available from 10 studies comprising 190 individuals. The mean difference of relative maximal CBV between glioma grades II and III ( LIMITATIONS: A substantial heterogeneity was found among included studies.
conclusionsGlioma grade III had higher relative maximal CBV compared with glioma grade II. A high diagnostic accuracy was found for all patients and astrocytomas; however, the diagnostic accuracy was substantially reduced when discriminating oligodendroglioma grades II and III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.